Hema e-Chart Registry of invasive fungal infections in haematological patients: Improved outcome in recent years in mould infections

Clinical Microbiology and Infection

Volumn 19, Issue 8, 2013, Pages 757-762

  Nosari, A M ^a   Caira, M ^b   Pioltelli, M L ^a   Fanci, R ^c   Bonini, A ^d   Cattaneo, C ^e   Castagnola, C ^f   Capalbo, S F ^g   De Fabritiis, P ^h   Mettivier, V ⁱ   Morselli, M ^j   Pastore, D ^k   Aversa, F ^l   Rossi, G ^e   Pagano, L ^b  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

^d Divisione di Ematologia   (Italy)

^e SPEDALI CIVILI   (Italy)

^f FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^g OSPEDALI RIUNITI   (Italy)

^h UNIVERSITY OF ROME TOR VERGATA   (Italy)

ⁱ CARDARELLI HOSPITAL   (Italy)

^j UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^k POLICLINICO   (Italy)

^l UNIVERSITY OF PERUGIA   (Italy)

more..

Author keywords

Attributable mortality; Galactomannan antigen; Haematological malignancies; Mould infections; Yeast infections

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; FLUCONAZOLE; GALACTOMANNAN; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ADULT; AGED; ARTICLE; CHEMOTHERAPY; ELECTRONIC MEDICAL RECORD; FEMALE; HEMA E-CHART REGISTRY; HEMATOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MOULD INFECTION; MYCOSIS; NEUTROPENIA; PRIORITY JOURNAL; PROPHYLAXIS; REGISTER; RISK FACTOR; SYSTEMIC MYCOSIS; YEAST;

EID: 84880509855     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12014     Document Type: Article

References (19)

1. Pagano L, Candoni A, Caira M et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM B - 2004 study. Haematologica 2006; 91: 1068-1075.
2. Baddley JW, Andes DR, Marr KA et al. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis 2010; 50: 1559-1567.
3. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic stem cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007; 44: 531-540.
4. Pagano L, Caira M, Candoni A et al. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica 2010; 95: 644-650.
5. Neofytos D, Horn D, Anaissie E et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of multicenter prospective antifungal therapy (PATH) alliance. Clin Infect Dis 2009; 46: 265-273.
6. Kontoyiannis DP, Marr KA, Park BJ et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the transplant-associated infection surveillance network (TRANSNET) database. Clin Infect Dis 2010; 50: 1091-1100.
7. Pagano L, Caira M, Nosari A et al. Hema e-Chart: Italian registry of prospective analysis of epidemiology, management and outcome of febrile events in patients with hematologic malignancies. J Chemother 2010; 22: 20-24.
8. Pagano L, Caira M, Nosari A et al. The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the Hema e-Chart project. Haematologica 2011; 96: 1366-1370.
9. Pagano L, Caira M, Nosari A et al. Etiology of febrile episodes in patients with acute myeloid leukemia: results from the Hema e-Chart registry. Arch Intern Med 2011; 171: 1502-1503.
10. Pagano L, Caira M, Rossi G et al. A prospective survey of febrile events in haematological malignancies. Ann Hematol 2011; 91: 767-774.
11. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) consensus group. Clin Infect Dis 2008; 46: 1813-1821.
12. Marr KA, Balajee SA, McLaughlin L et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004; 190: 641-649.
13. Marr KA, Carter RA, Boechk M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358-4366.
14. Ramos ER, Jiang Y, Hachem R et al. Outcome analysis of invasive aspergillosis in hematologic malignancy and hematopoietic stem cell transplant recipients: the role of novel antimold azoles. Oncologist 2011; 16: 1049-1060.
15. Pagano L, Caira M, Nosari A et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study. Clin Infect Dis 2007; 45: 1161-1170.
16. Tortorano A, Kibbler C, Peman J et al. Candidemia in Europe: epidemiology and resistance. Int J Antimicrob Agents, 2006; 27: 359-366.
17. Horn DL, Neofytos D, Anaissie EJ et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the Prospective Antifungal Therapy Alliance Registry. Clin Infect Dis 2009; 48: 1695-1703.
18. Nicolle MC, Bénet T, Thiebaut A et al. Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004 to 2009. Haematologica 2011; 96: 1685-1691.
19. Pagano L, Caira M, Picardi M et al. Invasive aspergillosis in patients with acute leukemia: update on morbidity and mortality - SEIFEM-C report. Clin Infect Dis 2007; 44: 1524-1525.